Hook & thesis
Oscar Health (OSCR) looks like a classic mispriced growth-insurance story: membership gains, public guidance for a 2026 profit turnaround, and valuation metrics that imply the market is pricing in permanent underperformance. The company guided to $18.7-19.0 billion in revenue and $250-450 million of operating earnings for 2026, while the stock trades around $14.33 with a market cap of roughly $4.27 billion and an EV of about $2.01 billion. Those headline numbers argue for upside if Oscar can execute on membership scale and medical-cost control.
My trade idea is a long position: entry near the current level, stop below the recent low, and a target back toward the 52-week high where the market would be valuing Oscar more on growth and profitability than fear. The setup is actionable with defined risk and a clear time horizon tied to the company bringing 2026 guidance to reality.
What Oscar does - and why the market should care
Oscar is a technology-forward managed health care insurer focused on the ACA individual marketplace, small group plans and Medicare Advantage, and it also sells a tech platform to payors/providers. The company's differentiator is a consumer-facing technology stack and data-driven care management (telehealth, chatbots and analytics) designed to reduce friction and lower medical loss ratios over time.
The market cares because Oscar's unit economics can swing dramatically with scale and modest margin improvement. Management's 2026 guidance - $18.7-19.0 billion in revenue and $250-450 million of operating income - implies Oscar expects to convert scale into positive operating leverage after a difficult 2025. If those projections hold, the stock's current EV/Sales of ~0.18 and P/S of ~0.38 would look unusually cheap relative to the growth and profit profile management expects.
Key recent data points and what they mean
- Q4 2025 results: revenue of $2.81 billion and an EPS loss of $1.24 per share, reflecting higher medical costs and morbidity headwinds. Management tied this weakness to 2025 dynamics but issued bullish 2026 guidance on 02/10/2026.
- 2026 guidance (02/10/2026): $18.7-19.0 billion in revenue and $250-450 million in operating earnings - a clear commitment to returning to profitability at scale.
- Balance-sheet/financials: market capitalization ~ $4.27 billion, enterprise value ~$2.01 billion, reported free cash flow ~$1.058 billion, and debt/equity ~0.44. Those figures support the view that the company has financial flexibility while it pushes for profitability.
- Valuation multiples: price-to-sales ~0.38, price-to-cash-flow ~3.98, price-to-free-cash-flow ~4.12, and a negative trailing EPS (-$1.49). The market is not pricing in Oscar achieving operating earnings in 2026.
- Technicals & sentiment: 52-week range $10.69 - $23.80, current price near $14.33, RSI ~61, MACD showing bullish momentum. Short interest sits around ~26 million shares, days-to-cover ~3.8 at recent volumes - enough to amplify moves if sentiment flips.
Valuation framing
At a market cap near $4.27 billion and EV ~$2.01 billion, Oscar is trading at EV/Sales of ~0.18 on trailing numbers and P/S of ~0.38. Those multiples are consistent with a market that doubts Oscar's path to sustained profitability. Management's 2026 operating earnings target ($250-450M) would materially change the narrative: if Oscar delivers even the midpoint (~$350M) and revenue hits the guided $18.85B, EV/EBIT would be roughly ~5.7x on a static EV basis - a multiple that implies meaningful upside from today's price if the market re-rates the stock toward profitable-growth comps. Put simply: the current multiple is cheap relative to a scenario in which the company executes on guidance and demonstrates durable medical-cost control.
Catalysts (what can re-rate the stock)
- Evidence of medical-cost stabilization - either sequential improvement in medical-loss trends or better-than-expected morbidity experience across key book segments.
- Quarterly membership disclosures and retention metrics that continue to show scale gains - scale reduces per-member fixed costs and improves unit economics.
- Regulatory tailwinds: the CMS Medicare Advantage capitation bump announced on 04/07/2026 (and broader rate predictability) can materially help MA economics and create positive industry flow-through for insurers.
- Execution on tech and cost initiatives - realization of expected savings from care-management programs or platform licensing wins that prove the differentiated tech stack delivers financial impact.
- Analyst upgrades or greater institutional accumulation after visible progress toward 2026 guidance.
Trade plan (actionable)
Direction: Long OSCR
Entry price: $14.33
Stop loss: $11.50
Target price: $23.80 (52-week high)
Horizon: long term (180 trading days) - I expect the trade to play out through multiple quarterly prints and cadence tied to 2026 execution. The timeframe gives Oscar room to show sequential improvement in medical cost trends, membership growth, and early signs of operating leverage toward the guided operating income range.
Rationale: Entry near $14.33 balances risk and reward - the stop below $11.50 sits beneath recent support and limits capital at risk while the target of $23.80 captures a re-rating to a more constructive multiple and the 52-week high. That target implies a >65% upside from the entry and assumes the market starts valuing Oscar on a path to positive earnings rather than current losses.
Risks and counterarguments
Every trade has downside; for Oscar the key risks are tangible and several are company-specific:
- Medical-cost inflation and morbidity spikes: the company missed expectations in 2025 because medical costs ran hotter than forecast. A recurrence or new adverse claims trends would push profitability further out.
- Subsidy/regulatory uncertainty: ACA subsidy availability and policy changes materially affect enrollment economics. Shifts that reduce subsidies or alter enrollment dynamics could compress margins.
- Execution risk on scale and tech ROI: Oscar's differentiation rests on tech-enabled care management. If these programs fail to deliver expected savings, the scale benefits may not translate into the operating leverage management is forecasting.
- Capital markets & liquidity risk: while free cash flow looks solid on recent numbers, volatility in the stock or external funding environment could raise financing costs, particularly if operating losses persist.
- Counterargument: The market could remain skeptical even if Oscar posts sequential improvement; the stock can stay range-bound until multiple quarters of demonstrated profitability and conservative guidance are evident. In that case, time-based decay on this position could work against holders unless they scale stops or size appropriately.
What would change my mind
I will lose conviction if one or more of the following occurs:
- Management materially cuts 2026 guidance or pushes the profitability timeline out further.
- Medical-cost trends deteriorate again on a sustained basis, showing recurring morbidity shocks rather than a single-year blip.
- Membership growth stalls or churn spikes, removing the scale economics that underpin the profit turnaround thesis.
Conclusion
Oscar Health is an asymmetric trade: the market's current pricing implies little chance that the company hits its 2026 operating earnings guidance, yet the balance sheet, cash-flow profile and membership growth suggest management has runway to prove it wrong. At $14.33 and an EV of roughly $2.01 billion, the upside to a re-rating is compelling if Oscar executes on medical-cost control and membership economics. The long-term (180 trading days) trade proposed above provides a structured way to participate in that outcome while keeping risk defined with a stop below recent support.
Execution is everything here: watch the next two quarterly prints for durable signs of margin improvement and retention trends before adding materially. If Oscar delivers on guidance and the narrative shifts from doubt to delivery, the market will likely reward a company that can combine growth and profitable scale.
Key points
- Oscar guided to $18.7-19.0B revenue and $250-450M operating income for 2026 (02/10/2026) - the single biggest catalyst for a re-rating.
- Valuation looks cheap: P/S ~0.38, EV/Sales ~0.18 with an EV of ~$2.01B versus market cap near $4.27B.
- Trade plan: Long at $14.33, stop $11.50, target $23.80, horizon long term (180 trading days).
- Primary risks are medical-cost volatility, regulatory/subsidy shifts, and execution on tech-driven cost savings.